Metabolismrelated pharmacokinetic drugdrug interactions with poly (ADPribose) polymerase inhibitors (Review).
Oncol Rep
; 47(1)2022 Jan.
Article
en En
| MEDLINE
| ID: mdl-34812476
ABSTRACT
Poly (ADPribose) polymerase (PARP) inhibitors, including olaparib, niraparib, rucaparib, talazoparib and veliparib, have emerged as one of the most exciting new treatments for solid tumors, particularly in patients with breastrelated cancer antigen 1/2 mutations. Oral administration is convenient and shows favorable compliance with the majority of patients, but it may be affected by numerous factors, including food, metabolic enzymes and transporters. These interactions may be associated with serious adverse drug reactions or may reduce the treatment efficacy of PARP inhibitors. In fact, numerous pharmacokinetic (PK)based drugdrug interactions (DDIs) involve the metabolism of PARP inhibitors, particularly those metabolized via cytochrome P450 enzymes. The present review aims to characterize and summarize the metabolismrelated PKbased DDIs of PARP inhibitors, and to provide specific recommendations for reducing the risk of clinically significant DDIs.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Interacciones Farmacológicas
/
Inhibidores de Poli(ADP-Ribosa) Polimerasas
Tipo de estudio:
Guideline
Límite:
Humans
Idioma:
En
Revista:
Oncol Rep
Asunto de la revista:
NEOPLASIAS
Año:
2022
Tipo del documento:
Article